HomeAI · summaries
Storia in 2 fonti
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
- ·
qz.com
AstraZeneca tozorakimab COPD Phase 3 trial results 2026
The drug reduced flare-ups in a broader patient population than existing COPD biologics, with U.S. approval expected in early 2027